Welcome Message

Hematology Congress 2023 invites the participants from all across the globe to take part in this flagship conference with the theme “Defining a New Outlook and Forefront Research in Hematology and Cell Therapy”.

It would be our immense pleasure to invite you all to the 2nd World Summit on Hematology and Cell Therapy which will be held during August 03-04,2023 as webinar. Brings upon a brand new programmer to share new concepts and discuss all the innovations within the field of Hematology and Cell Therapy.

Hematology Congress 2023 congress is expected to be the largest and best platform for all the Scientists, hematologists, Pathologists, Surgeons, Nurses, Research Scholars, Business Professionals, Students who are working in the branch of Hematology to give speaker talks, prompt keynote presentations, workshops and exhibitions where researchers and associations to exchange their ideas and discuss the advancements of modern diagnostics and treatment methods for Hematologic Disorders and new approaches emerging in Hematology etc..

Regards
Organizing Committee
Hematology Congress 2023

About Conference

Hematology Congress 2023 gives a creative research area in motivating young ones in developing research fields and provides cutting edge technology for massive innovations. Hematology Congress 2023 covers an in-depths area of science at micro and macro level thus helping to learn about synthesis, characterization, properties and numerous other benefits of Hematology. Meet notable personalities all under one common platform for sharing ideas by exclusive scientists, passionate researchers, and prestigious delegates across the globe. We are looking further to current meeting success by bringing revolution in the field of Hematology through sharing your concepts, views, and experiences of research work under one roof for a more robust world. We are a globally acknowledged and trusted organization to provide unique scientific and business services through our Journals and we are expanding the functionality of our International conferences.
Our main principle is to support original research work, share and exchange the ideas of authors from various institutions within the world. Our journals act as triumphant platform for numerous scholars including teaching professors and researchers.
Meet the Global Influenced Experts and Speakers to talk about on recent advancements in the field of medical and engineering to improve health and treatment with additional innovations.

Why to attend?
Hematology Congress 2023 is a unique platform to share the knowledge on current research. The main aim of Hematology Congress 2023 is to discuss the recent approaches/advancements and challenges faced in the field of Hematology and transfusion medicine. It is a great opportunity to meet the biggest collection of members from the Hematology people group. The latest advancements and strategies of the most current situations in the field of Hematology are signs of this gathering.

Benefits of conferences:

• Young Scientists can get acceptable and timely data by this Forum.
• Provide a chance for analysis interaction and established senior investigators across the world within the field.
• Share the concepts with each eminent researchers and mentors.
• It’s a good privilege for young analyzers to find out regarding the analysis areas for increasing their research data.
• A platform for collaboration among young researchers for higher development.
• Young individual Award recognition certificate and reminder to the winners.
• Our conferences offer the most effective Platform for your analysis through oral shows.
• Learn about career improvement with all the newest technologies by networking

Target Audience:

• Hematology and Cell Therapy Professionals
• Doctors
• Young analysis scientists
• Hematology Associations and Societies
• Producing Medical Devices firms
• Administrators of firms within the field of Hematology
• Leading scientists
• Professors.
• Fellows or postdoctoral students
• Researchers, CEOs
• Business Delegates
• Health care professionals

Founders and staff of the connected firms.

Sessions and Tracks

Track 1: Hematology
Hematology is a department of clinical medicine which offers with prognosis and treatment of blood problems and blood cancers. Hematologists and hematopathologists mainly work together to form a determination and convey the most suitable treatment if necessary. Diseases treated under Hematology are

• Acute Leukemia
• Chronic Leukemia
• Plasma Cell disorders
• Lymphoma – Hodgkin / Non Hodgkin
• Myeloproliferative Neoplasms
• Thalassemia and other haemoglobinopathies
• All types of coagulation and thrombotic disorders
• Hemoglobin and platelet disorders

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 2: Cell Therapy
Cell Therapy is the transfer of cells into a patient with a goal of improving the disease. From beginning blood transfusions were considered to be the first type of cell therapy to be practiced as routine. Later, Bone marrow transplantation has also become a well-established concept which involves treatment of much kind of blood disorders including anemia, leukemia, lymphoma and rare immunodeficiency diseases. Alternative medical practitioners perform cell therapy in the form of several different names including xenotransplant therapy, glandular therapy, and fresh cell therapy. It has been claimed by the proponents of cell therapy that it has been used successfully to repair spinal cord injuries, strengthen weaken immune system, treats autoimmune diseases like AIDS, help patients with neurological disorders like Alzheimer’s disease, Parkinson’s disease  and epilepsy.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 3: Stem Cell Research
Advances in hematopoietic stem cell immunology and histocompatibility have an impact on HSC transplantation breakthroughs. Immunotherapy is an important part of the HSC transplant process. In a number of ways, HSC transplantation is connected to cancer immunotherapy. Hematologists who investigate HSCs have become pioneers in the field of induced pluripotent stem cells, which is still in its infancy (iPS). Using the iPS cell fields reprogramming principles, T cells are now being reprogrammed to generate memory stem cells. Hematology, cancer, stem cell biology, and immunology have all been merged to change the definition of a hematologist.

• Allogeneic stem cell transplant
• Autologous stem cell transplant
• Blood forming stem cell transplant

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 4: New Drug Development in Hematology
The procedure of bringing new therapeutic medicines for the treatment of damage into the commercial center is a time-consuming and expensive one. When everything is said and done, the most recent techniques for tranquillize disclosure are selected. Medication repurposing asserts the ability to quickly introduce fresh restorative strategies into clinical trials with minimal effort. By employing their known toxicological, pharmacology, and pharmacokinetics, identified on-patent or off-patent drugs with undiscovered anticancer movement can be quickly first in class into clinical testing for this unique indicator. Pedantic assembling can take a look at the medicine confession sector in this way, and smaller biotechnology companies can "de-risk" early-stage placid declaration projects. Some inferential techniques for identifying sedate repurposing opportunities are highlighted in this article, with a focus on hematopoietic malignancies.

• Ruxolitinib
• Acalabrutinib
• Givosiran
• Hematologic malignancies

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 5: Disorders of Vascular Bleeding
Vascular bleeding problems end result from defects in blood vessels, commonly inflicting petechiae, purpura, and bruising however, besides for hereditary hemorrhagic telangiectasia, seldom main to severe blood loss. Bleeding may also end result from deficiencies of vascular and perivascular collagen in Ehlers-Danlos syndrome and in different uncommon hereditary connective tissue problems. Hemorrhage can be a outstanding characteristic of scurvy or of immunoglobulin a related vasculitis, an allergic reaction vasculitis not unusual place at some stage in childhood.
Hemorrhage problems are incited through vascular malformation or deficiency. They are connected with cutaneous or mucosal flat or perceptible purpura. These problems are a heterogeneous meeting of instances categorized through smooth staining, petechiae, mucosal bleeding, bruise, and impulsive hemorrhage from small vessels. The essential imperfection is said to be furthermore with inside the vessels themselves or with inside the perivascular connective tissue. The generally used purpura generally describes subcutaneous bleeding, so that it will be connected to vessel wall abnormalities or platelet abnormalities of which a few are hereditary and even as the others are acquired.

• Autoerythrocyte Sensitization
• Dysproteinemias Causing Vascular Pupura
•  Hereditary Hemorrhagic Telangiectasia
• Pupura Simplex
• Senile Purpura

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 6: COVID-19 and Hematology
COVID-19 gives as complex medical manifestations, from flu-like signs and symptoms to a couple of organ failure and death. According to the prognosis and remedy protocol for novel coronavirus pneumonia posted through the National Health Commission of China, there are 4 severity tiers of COVID-19 primarily based totally at the medical manifestations: mild, moderate, intense, and essential disease. Severe, in particular essential, instances are normally complex through different organ dysfunctions, such as septic shock, coronary heart failure, and disseminated intravascular coagulation (DIC).
In medical practice, a few thrombotic headaches were mentioned, such as ischaemic limbs, strokes, and venous thromboembolism. Venous thromboembolism is not unusual place in sufferers with intense disease. Although numerous research mentioned that reduced platelet matter and improved D-dimer have been related to intense COVID-19 and excessive mortality, few research have systematically assessed hematological and coagulation parameters amongst sufferers with moderate, intense, and essential COVID-19

• Full blood count and biochemistry findings
• The emerging role of biomarkers procalcitonin, ferritin and C-reactive protein in the prognosis
• Coagulation complications
• Blood and hematopoietic stem cell donation

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 7: Transfusion Medicine
A physician who looks after the maintenance of an adequate blood supply, blood donor and patient-recipient safety is specialized in transfusion medicine. It deals with the issues of clinical transfusion practices, immunohematology, blood donation and other clinical tests for transfusion transmittable diseases, patient blood management, therapeutic apheresis, cellular therapy and coagulation. Blood Transfusion is a medical procedure where donated blood is transfused to a recipient. Blood transfusion helps patients to survive from iron deficiency Anaemia, Sickle cell ailment and haemorrhage. The requirement of blood is progressively growing even though some branches of medicine have brought down its certainty. The transfusion medicine specialists predict good scenarios by the year 2025, at best in the developing countries.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 8: Blood Disorders Diagnosis & Treatment
Blood disorders are of different types and are categorized based on the various components in blood – red blood cells, white blood cells, and platelets. Blood disorder involves blood proteins that are integral in the clotting of blood. Chemotherapy, Radiation is the prescribed treatments for Lymphoma and Leukaemia. Stem cell transplant/chemotherapy can prolong life for patients suffering with multiple myeloma. If there isn’t sufficient platelet or too many platelets then the common platelet disorders obtained are Immune Thrombocytopenia and Thrombasthenia. In certain cases treated with medicines and involves platelet transfusion and severe cases of a bone marrow transplant. Iron deficiency anemia can be treated by intake of iron pills. In some cases injection of a synthetic hormone to stimulate the growth of red blood cells is prescribed for chronic diseases related anemia. For sickle cell anemia, bone marrow transplant or stem cell transplant is the only treatment for the condition.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 9: Pediatric Hematology
Pediatric Hematology is a subdivision of Hematology which handles the blood disorders in children and treats them with care. Due to lack of knowledge and awareness among the children may lead to a delay in diagnosis and treatment of blood disorders. Blood disorders contain problems with red blood cells, white blood cells, platelets, coagulation or bone marrow. The blood disorders in the Paediatric age group are often different from that in adults hence needing specialised care. Haematologists have the experience to manage and treat a child or youngster with hematologic disorders. Infants or Children with blood diseases and blood cancers need special attention than adults.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 10: Hematology Oncology
Hematology Oncology specialists, specialize in treating, screening and preventing blood malignancy and cancer. Hematology-oncology assimilates such sicknesses as anaemia, haemophilia, sickle cell disease, thalassemia, leukaemia and lymphoma. In clinic they oversee Chemotherapy regimens and work with Radiologists and Radiation Oncologists. Experts provide healthcare to the hospitalized patients by treating their blood ailments such as sickliness, draining scatters, and coagulating issues. Hematologists - Oncologist specialize in treating blood cancers such as-

• Hodgkin’s and non-Hodgkin
• Lymphoma
• Leukaemia
• Multiple myelomas

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 11: Blood Transfusion
Blood transfusion can be life-renewing and is a primary element of many advanced surgeries and clinical interventions. In spite of the fact that blood components are expensive they may periodically have serious deleterious effects and supplies are inadequate. By overlooking inessential and unreasonable transfusions is good for patients and have to ensure blood supplies encounter the increasing demands of an ageing population. Once in a while, ailment can make it difficult for your body to produce good blood. A few conditions that might require transfusion treatment include:

• Anaemia
• Cancer
• Haemophilia
• Kidney disease
• Liver disease
• Severe Infection
• Sickle Cell disease
• Thrombocytopenia

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 12: Leukaemia and Lymphoma
Leukaemia either it could be acute or chronic. In acute leukaemia, the cancer develops rapidly. Chronic leukaemia is more common and pile up slowly at the beginning stages. There are four main types of leukaemia each categorized by the multiplication and origins of the cancer cells. These include:

• Acute myeloid leukaemia
• Chronic myeloid leukaemia
• Acute lymphocytic leukaemia
• Chronic lymphocytic leukaemia

Lymphoma pointedly strikes the lymph nodes. Based on the origin of the cancer cells the type of lymphoma is determined. It might begin in the lymphatic system or in the white blood cells and these cancers are also called non-Hodgkin lymphomas. They prevail when T- or B-cells within white blood cells become malignant.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 13: Therapeutic Apheresis
Apheresis is a process of separating the individual components of blood using a machine. Apheresis is commonly done on donors where the entire blood is filtered to obtain individual components i.e., red blood cells, platelets, plasma based on specific gravity to use for transfusion in different patients. Apheresis can also be used as a therapeutic agent to treat various disorders. Therapeutic apheresis is a treatment which removes abnormal cells in the blood which are correlated with a certain disease states. The basic premise of therapeutic apheresis is that removal of certain pathologic cells will reduce organ or tissue damage and may permit reversal of a pathologic process. In order to prevent volume depletion during therapeutic plasmapheresis, the volume of plasma removed must be replaced by plasma, colloid, or crystalloid. Some complications differ depending on whether the replacement fluid is allogeneic (donor) plasma or albumin.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 14: Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation
Multiple myeloma is a cancer that arises from a type of white blood cells called as plasma cell myeloma. Plasma cells become abnormal, proliferate when tumors accumulate in the different parts of the body especially in the bone marrow. Myeloma is diagnosed and monitored by measuring the levels of paraproteins. Amyloidosis is a rare disease that occurs when an abnormal protein called amyloid builds up in your organs and interferes with their normal function. Amyloid is formed from several different types of protein in the body. Treatments for amyloidosis may include medications to reduce amyloid production and to control symptoms and some people may benefit from organ or stem cell transplants. A stem cell transplant also called a bone marrow transplant which treats certain types of cancer. Depending on where the stem cells come from the transplantation is defined either peripheral stem cell transplant or cord blood transplant. Hemopoietic stem cells give rise to other blood substances by a process called Hemopoiesis in the red bone marrow. Hemopoietic stem cell transplants are used in the treatment of immune system disorders and cancers.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 15: Patient Blood Management
Blood transfusion comprises of all clinical aspects of blood transmission and promotes safe practice and proper use of blood components. There is a risk and also benefits of transfusion as well as close monitoring of patients. Blood is transmitted to patient when there is evidence for potential benefit. It is vital to follow an evidence-based and multidisciplinary approach for the patient care in need for blood transfusion. Patient Blood Management (PBM) incorporates with patient health condition and clinical management decision-making process. PBM can reduce allogeneic blood transfusions and health-care costs while making sure that blood components are handy for patients. This includes implementation of appropriate indications, depreciation of blood loss and enhancement of patient red cells.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 16: Immunohematology
Immunohematology is the study of antigens and antibodies present on blood cells and plasma associated with blood transfusion. Antibodies in the patient's plasma or Antigen on the patient's red cells can be identified from a simple tube and gel tests to more complex absorption and elution techniques as well as advanced molecular techniques. A wide range of immune-haematological techniques are used to identify hematological conditions such as auto immune haemolytic anaemia and resolve the diagnostic problems in these patients. Molecular technique is immensely used in immunohematology which acts on the antigen profile of patients and rectifies problems.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 17: Case reports of Hematology
A case report is a description of important medical observations that are unnoticed or unobserved in clinical trials. A case report is a summarization of the signs, symptoms, diagnosis and treatment of an individual patient. Hematology case reports have helpful roles in medical research and evidence-based drugs. Specifically, they need facilitated recognition of rare or unusual clinical condition, unusual side effects to therapy or response to treatment and special use of imaging modalities or diagnostic tests to assist diagnosis of a disease. Case reports might also play a key role in guiding the personalization of treatments in clinical aspects.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 18: Thalassemia
Thalassemia is hereditary blood disorder caused when the body doesn’t make enough hemoglobin which is an important part of red blood cells. It is inherited from parents to children through genes and may cause a person feel tired, weak, Lack of appetite and short of breath. Haemoglobin carries oxygen to all cells in the body and there are two types called alpha and beta. The mutation of two adjacent genes which control the making of alpha globin protein can cause alpha thalassemia. Beta thalassemia disorder occurs due to genetic deficiency in production of beta globin protein.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 19: Thrombosis and Coagulation
Coagulation mechanism involves in stopping the flow of blood due to an injured or defective vessel wall. The change within the blood into an insoluble gel when injured is blood coagulation. The Coagulation factors are characterized by procoagulatory and anticoagulatory which are in balanced state under normal conditions. The fibrinolytic system prevents the blood clots being problematic for the blood components and this process requires phospholipids, calcium and coagulation factors. Thrombosis summarizes as a variation in the clotting capacity of the blood which partially or entirely stops the flow of blood through that vein. Complications of thrombosis can be life-threatening to a person. When blood clots blocks while blood flows through the veins leads to venous thrombosis. Arterial thrombosis is when the blood clot blocks an artery while oxygen-rich blood carried from heart to the body.

Treatment may include-

• Anticoagulants
• Thin tubes and stent helps to open the blocked vessels
• Medicines to prevent clots

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Track 20: Transfusion Transmissible Infections
Regardless of advancement in screening technologies while blood transfusion, there is still a risk of transfusion-transmitted infectious diseases. These infectious diseases can be reduced by donor exclusion, screening for serological infection markers or nucleic acid testing (NAT) by viral gene amplification. Nevertheless, blood-borne infection is transferred through transfusion of infected blood donated by apparently healthy and asymptomatic blood donors. Infectious agents involved are of various types which include-

• Hepatitis B (HBV)
• Hepatitis C (HCV)
• Human immunodeficiency (HIV-1/2)
• Human T-cell lymphotropic (HTLV-I/II)
• Cytomegalovirus (CMV)
• West Nile (WNV)
• Trypanosomiasis
• Transmissible Spongiform Encephalopathy (TSE)
• Malaria and Dengue Viruses

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Market Analysis

Hematology Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2027. Blood disorders are substantial health and economic burden in worldwide populations. The growing prevalence of common blood disorders such as anemia particularly among women and hemophilia has been driving clinical advances in the hematology market. The prevalence of certain blood cancer in developed countries is also bolstered awareness for hematology testing. The Global Hematology Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

The increasing incidence of blood-related disorders is expected to propel the growth of the global hematology market. The rising incidence of blood cancer is a major factor contributing to the growth of the market. For instance, according to GLOBOCAN 2018, more than 1.85 million new blood cancer cases are expected to be diagnosed in 2040 across the globe. Furthermore, according to the American Cancer Society, Non-Hodgkin lymphoma is one of the more common types of cancer in the U.S., accounting for 4% of all cancer cases. An estimated 74,680 patients were diagnosed with Non-Hodgkin lymphoma in the U.S. in 2018. In addition, increasing incidence of hemophilia and sickle-cell anemia is expected to drive the growth of the global hematology market. For instance, according to the World Federation of Hemophilia’s (WFH) 2018 statistics, around 440,000 people had hemophilia, out of which around 173,000 people were diagnosed with hemophilia A or B in 2017 globally. Furthermore, as per the World Health Organization, in 2018, the prevalence of anemia in children was around 45% and 12% in men, and it is increasing rapidly all over the world. Similarly, According to the National Institute of Health (NIH), anemia affects 30% of women of reproductive age and 40% of pregnant women, globally. Stringent regulatory and reimbursement policies on product launches, as well as product recalls due to safety violations are projected to hamper the growth of the market over the forecast period. For instance, in April 2017, Sysmex, a Japanese medical devices company recalled 3,682 XN Series Automated Hematology Analyzers, owing to increases in incidences of fire caused due to improper alignment of an internal protective sheet that protects electronic components from salty reagents used in hematological sample analysis.

Furthermore, an increasing number of product launches is expected to propel the market growth over the forecast period. New product launches by key players operating in the global market are expected to propel the growth of the global hematology market. For instance, in May 2018, Beckman Coulter, a Danaher Corporation company that develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing, launched the DxH 900 hematology analyzer which performs complete blood count and white blood cell differential tests with minimal repeats for application in mid-to high-volume clinical laboratories. In February 2018, Horiba, a Japanese manufacturer of precision instruments for measurement and analysis, launched the Yumizen G range of semi-automatic to fully automatic hemostasis solutions for clinical testing. Moreover, the increasing adoption of certifications for quality enhancement by key players operating in the global hematology market is expected to propel the market growth over the forecast period. In November 2017, Sysmex received CLIA Waiver certification under the U.S. regulatory approval system for the XW-100 automated hematology analyzer. It is the latest product in the hematology field targeting the U.S. market.